2BBBullish & Bearish
Halozyme Therapeutics, Inc. (HALO) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 36 out of 100.
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
Halozyme Therapeutics, Inc.’s current 2BB score is 36 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 12 | Very Low |
| Momentum | 48 | Stable |
| Financial strength | 61 | Strong |
| Quality | 100 | Very Strong |
| Risk | 0 | Very Low |
| CEO | Helen I. Torley |
| Headquarters | San Diego, California, United States |
| Founded | 1998 |
| Employees | 423 |
| P/E ratio | 27.54 |
| 52-week range | $52.72 – $82.22 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-01-26 | — | 2.6683 | — | $547.82M |
| 2026-11-02 | — | 2.3378 | — | $484.56M |
| 2026-08-06 | — | 1.8727 | — | $415.64M |
| 2026-05-12 | — | 1.5606 | — | $366.23M |